Predictive Oncology’s Q4 2024 Financial Report and Corporate Update
Pittsburgh, PA – April 1, 2025 – Predictive Oncology, Inc. (Nasdaq: POAI), a pioneering company harnessing the power of artificial intelligence (AI) and machine learning (ML) to accelerate oncologic drug discovery, reported their financial and operational results for the quarter ended December 31, 2024.
Financial Highlights
For the year ended December 31, 2024, Predictive Oncology reported a loss from continuing operations of approximately $10.8 million on total revenue of $1.6 million. This loss can be attributed to the significant investments the company has made in research and development to advance its mission in the field of oncology.
Corporate Update
The company’s extensive biorepository of tumor samples and CLIA laboratory continue to be essential assets in their mission. Predictive Oncology has been able to leverage these resources to provide valuable data and insights to pharmaceutical partners, contributing to the development of novel oncology therapeutics. The company’s collaborations with leading institutions and research organizations further strengthen its position in the industry.
Impact on Individuals
Although the financial results do not directly affect individuals, the work being done by Predictive Oncology holds great potential for those battling cancer. The company’s advancements in oncologic drug discovery could lead to the development of new and more effective treatments. As a result, the lives of millions of cancer patients may be improved or even saved.
Impact on the World
The global cancer burden is a significant public health issue, with an estimated 19.3 million new cases and 9.9 million deaths in 2020. Predictive Oncology’s innovative approach to drug discovery and development has the potential to make a substantial impact on this issue. By accelerating the process of identifying effective treatments, the company could contribute to a reduction in cancer-related morbidity and mortality, ultimately improving the quality of life for countless individuals around the world.
Conclusion
Predictive Oncology’s Q4 2024 financial report and corporate update underscore the company’s continued commitment to advancing oncologic drug discovery and development. Despite the significant investments being made, the potential benefits to the field of oncology and, ultimately, to individuals battling cancer, make this a worthwhile endeavor. As the company continues to collaborate with leading institutions and research organizations, the future of Predictive Oncology looks bright, filled with hope and the promise of new, effective cancer treatments.
- Predictive Oncology reported a loss from continuing operations of $10.8 million on total revenue of $1.6 million for the year ended December 31, 2024.
- The company’s extensive biorepository of tumor samples and CLIA laboratory are crucial assets in their mission to accelerate oncologic drug discovery.
- Predictive Oncology’s work has the potential to significantly impact the lives of millions of cancer patients around the world.
